Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsBusiness

Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolariSing neuromuscular blocking agents (NMBAs) after surgery.

April 22, 2021 / 10:28 AM IST
Pharma

Pharma

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Caplin Point Laboratories on Thursday said its subsidiary has received approval from the US health regulator for Neostigmine Methylsulfate Injection.

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolariSing neuromuscular blocking agents (NMBAs) after surgery.

"Caplin Steriles Ltd (Caplin) has been granted final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Neostigmine Methylsulfate Injection USP in the strengths of 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL)," Caplin Point Laboratories said in a regulatory filing

Multiple-dose vial presentations, a generic therapeutic equivalent version of (RLD), BLOXIVERZ Injection, of Exela Pharma Sciences, LLC, USA.

Quoting IQVIA (IMS Health) data, Caplin Point Laboratories said Neostigmine Methylsulfate Injection had US sales data of approximately USD 20 million for the 12-month period ending Dec 2020.

Close
Shares of Caplin Point Laboratories were trading 3.14 percent higher at Rs 523.15 apiece on BSE.
PTI
first published: Apr 22, 2021 10:29 am

stay updated

Get Daily News on your Browser
Sections